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Novel emerging therapies for Duchenne muscular dystrophy (DMD), such as antisense oligomer (AO) 
mediated exon skipping, have generated the need of understanding the natural history study of the 
targeted genotype subgroups. Most natural history studies are focused on ambulant subjects; 
therefore very little data exists on non-ambulant DMD. Specifically targeting skippable deletions, we 
aim to assess the natural history of DMD through a composite assessment tool capable of capturing 
disease progression beyond loss of ambulation. With a recruitment target of 80 DMD patients with 
AO-skippablemutations across 5 centres (i.e. London, Newcastle, Paris, Leiden, and Nijmegen), 
subjects are assessed every 6 months for 3 years according to an internationally agreed shared 
protocol, including the 6-minute walk test (6MWT), the North Star Ambulatory Assessment (NSAA), 
as well as the Performance of Upper Limb (PUL) and the MyoSet (i.e. MyoGrip MyoPinch and 
MoviPlate). Both ambulant and non-ambulant subjects undergo upper limb evaluation, respiratory 
function test and quality of life questionnaires. Serum biomarkers, including antidystrophin 
autoreactive T cells, are also evaluated. To date, 57 DMD subjects have been recruited (London, 
Newcastle and Paris), aged 5 to 18 years; 33 ambulant and 24 non-ambulant; 49 with 18 month 
follow-up data. The prevalence of autoreactive T cells is ~16%. Using multilevel modelling, nested 
within a random effect for centre/site, we describe the decline in motor functional parameters over 
time. We further investigate the relationship between these different variables, focussing on upper 
body measures, in relation to NSAA score and the 6MWT. We explore any relationship differences 
between boys with different skippable deletions. Our study offers a comprehensive up-to-date 
natural history data across all stages of ambulation for DMD subjects with skippable mutations 
amenable to AO therapies.  
